SpinaFX Medical Receives FDA IDE Approval for Triojection Pivotal Trial in Contained Herniated Lumbar Discs
核心洞察
The FDA has granted SpinaFX Medical (搜索) an Investigational Device Exemption (IDE) for Triojection (搜索), enabling a pivotal U.S. clinical trial for a minimally invasive lumbar disc treatment.
The prospective, randomized, multicenter trial will enroll 300 patients across up to 30 U.S. sites, comparing intradiscal ozone/oxygen injection plus nerve root block to nerve root block alone.
The study targets patients with contained herniated lumbar discs who have failed conservative therapy, addressing a recognized therapeutic gap between failed conservative care and surgery.
SpinaFX Medical (搜索), a clinical-stage medical device company based in Canada, announced on June 9, 2026 that the U.S. Food and Drug Administration has granted an Investigational Device Exemption (IDE) for Triojection (搜索)®, its minimally invasive, image-guided therapy for intravertebral disc disorders. The IDE approval permits the initiation of a pivotal U.S. clinical trial designed to evaluate intradiscal ozone/oxygen injection plus nerve root block compared with nerve root block alone in patients with contained herniated lumbar discs that have failed conservative therapy.
"This IDE is another major milestone for SpinaFX, years in the making. My European colleagues and I have been extensively involved in the clinical development and refinement of intradiscal ozone in Europe and Canada," said Prof. Kieran Murphy, Interventional Neuroradiologist at Toronto Western Hospital and Co-Founder and Chief Medical Officer of SpinaFX Medical (搜索). "While this approach has been used in certain markets outside the United States, the U.S. pivotal trial is intended to evaluate its safety and effectiveness in a rigorous clinical setting and to help determine whether it may become an additional minimally invasive option for appropriately selected patients in the USA."
Trial Design and Endpoints
The planned study is a prospective, randomized, multicenter trial expected to enroll 300 patients across two treatment arms at up to 30 specialty spine treatment sites in the United States. The trial is designed to evaluate whether adding intradiscal ozone/oxygen injection treatment to conventional nerve root block can improve pain and functional outcomes versus nerve root block treatment alone.
Primary and secondary endpoints are expected to include clinically meaningful measures of pain and function assessed at 6, 12, 18, and 24 months. In addition to safety and effectiveness, the study will also evaluate the health economics of adding Triojection (搜索) to conventional treatments. Site and core laboratory partnerships are currently under discussion to support study execution and data quality.
Addressing the Therapeutic Gap
Treatment of contained disc herniation remains an area of significant unmet clinical need. According to SpinaFX's clinical background, there is a recognized "therapeutic gap" for herniated disc treatment between failed conservative care and surgery. Leaders in interventional spine care have argued for more consistent, minimally invasive, image-guided treatment options for these patients.
Published literature cited by SpinaFX reports encouraging clinical findings outside the United States for intradiscal ozone therapy, providing background support for further investigation. However, the therapy remains investigational in the United States, and any regulatory, clinical, reimbursement, or commercial outcomes will depend on the conduct and results of the trial and subsequent FDA review processes.
Regulatory Pathway and Market Implications
The IDE approval follows Triojection (搜索)'s receipt of FDA Breakthrough Device Designation in August 2025, for which SpinaFX acknowledged MCRA (搜索) for its expert assistance. The IDE permits a pivotal U.S. study designed to generate the clinical evidence needed to support a future application for FDA marketing authorization. The condition affects millions of global patients annually, representing a large addressable market with significant unmet need and high associated healthcare costs.
Prior international studies performed by Dr. Murphy and colleagues, along with meta-analyses of other investigators' work summarized by SpinaFX, provide background context for the investigational rationale. The company, with representation in nine offices worldwide, is focused on developing minimally invasive, image-guided therapies for patients with disc-related pain and disability, aiming to address the gap between conservative care and surgery with evidence-based therapies designed for broad clinical accessibility.